Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04597840
Other study ID # 69HCL20_0215
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 25, 2021
Est. completion date October 2024

Study information

Verified date June 2022
Source Hospices Civils de Lyon
Contact Guillaume PASSOT, Pr
Phone 4 78 86 23 71
Email guillaume.passot@chu-lyon.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Incisional hernia is one of the most common complications of abdominal surgery and carries a significant burden for both patients and the economic health service. However, no consensus for the surgical treatment of incisional hernia in contaminated field is currently available. The purpose of the COMpACT-BIO study is to investigate the clinical and economic benefit of the use of biosynthetic mesh in contaminated incisional hernia repair.


Description:

The current standard of incisional hernia repair is reinforcement with permanent synthetic mesh. However, permanent synthetic mesh is contraindicated in contaminated surgical field due to higher risk of postoperative infection. In order to resist to infection, absorbable meshes, such as biological and biosynthetic meshes, have been developped. However, some controversies exist about the clinical benefit of biological meshes in the long term. Reasons for theses controversies are their overall risk of complication and recurrence and the lack of consensus in which surgical technique to apply. Moreover, the financial cost of biological meshes is very high. Recently developed, biosynthetic meshes appear to be a promising option ; Compared to biological meshes, they seem to have several advantages. However, such data demonstrating the beneficial use of biosynthetic mesh in contaminated incisional hernia repair is not available. In this regard, the COMpACT-BIO study aims to investigate the clinical and economic benefit of the use of biosynthetic mesh in contaminated incisional hernia repair in comparison to the standard of repair. This is a multicenter, prospective, longitudinal and randomized study, which also offers a standardized technique of repair.


Recruitment information / eligibility

Status Recruiting
Enrollment 108
Est. completion date October 2024
Est. primary completion date October 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility All the following inclusion criteria must be fulfilled: - Age =18 years old - Physical status ASA < 4 - Patient with a mid-line IH - Patient presenting with an IH without loss of domain - Surgical indication in elective surgery - "Potentially contaminated" grade III surgical environment according to the classification of the modified VHWG - Cure of mid line IH feasible according to the defined standard technical modality (placement of a retromuscular prosthesis) - No emergency surgical procedure - Status of social insured or entitled to a social insurance - Informed and signed consent of the patient after clear and appropriate information The exclusion criteria are as follows: - One or multiple incisional hernia out of the midline incision - Pregnancy, breastfeeding, parturient or childbearing patients without contraception - Known allergy to tetracyclines; - Persons protected by law

Study Design


Intervention

Procedure:
Incisional hernia repair with reinforcement of biosynthetic mesh
The biosynthetic mesh (Phasix or Bio-A meshes) will be placed as a sublay in the retromuscular position to reinforce midline fascial closure. All the surgical procedure (including placement and fixation of the mesh) will be performed according to a standardized protocol.
Incisional hernia repair with simple suture or synthetic mesh reinforcement.
Based on the discretion of the surgeon, the incisional hernia repair will be done by simple suture or by synthetic mesh reinforcement. All the surgical procedure (including placement and fixation of the mesh if applicable) will be performed according to a standardized protocol.

Locations

Country Name City State
France Hôpital Lyon Sud Pierre-Bénite

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of incisional hernia recurrence The rate of incisional hernia recurrence will be evaluated by radiologic imaging. 3 years after surgery
Secondary Days of hospitalization related to incisional hernia repair Number of days of hospitalization related to hernia repair-related complications will be reported. For 3 years after surgery
Secondary Incidence of re-operation related to incisional hernia repair Incidence of incisional hernia repair-related complications leading to re-operation will be reported. For 3 years after surgery
Secondary Incidence of wound events Incidence of incisional hernia repair-related wound complications, such as wound infection will be reported. 1 month from surgery date, then 3-, 6- 12-, 24- and 36 months from surgery date
Secondary Incidence of revision surgery or interventional radiologic procedure Incidence of revision surgery or interventional radiologic procedure related incisional hernia repair-related wound complications will be reported. 1 month from surgery date, then 3-, 6- 12-, 24- and 36 months from surgery date
Secondary Rate of early incisional hernia recurrence The rate of incisional hernia recurrence evaluated by physical examination and then confirmed by radiologic imaging will be reported. 1 month from surgery date, then 3-, 6- 12-, 24- and 36 months from surgery date
Secondary Incisional hernia specific quality-of-life assessment Self reported clinical symptoms before and after incisional hernia repair will be done using a modified version of the Carolina Comfort Scale . Severity of pain and discomfort pre and post repair will be measured during different daily activities (item). Each item is scored 0-5 (0= no symptom ; 5= worst symptom). Pre and post-surgery (1 month from surgery date, then 3, 6, 12, 24 and 36 months from surgery date).
Secondary Number of healing days At each clinical examination, the time between surgery and the end of median scar care will be measured. 1 month from surgery date, then 3-, 6- 12-, 24- and 36 months from surgery date
Secondary Rate of screening failure The proportion of patients who did not receive the surgical procedure proposed by the study, and the related reasons of screening failure will be reported. 48 months after the start of the study
Secondary Assessment of health care consumption related to health care status The cost / quality ratio will be measured using the consumption of health care and the health status. In one hand, each health care action will be reported (by the patient or the caregiver) and then the total cost relative to the health care will be measured. In another hand, self-reported health status before and after incisional hernia repair will be done using the EQ-5D-5L questionnaire. pre and post-surgery (1 month from surgery date, then 3, 6, 12, 24 and 36 months from surgery date).
See also
  Status Clinical Trial Phase
Terminated NCT01981044 - SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support in Ventral Hernia Repair N/A
Completed NCT03945357 - Reducing INfection at the Surgical SitE With Antibiotic Irrigation During Ventral Hernia Repair (RINSE Trial) Phase 3
Suspended NCT02505204 - PVB With vs. Without Clonidine for Ventral Hernia Repair N/A
Recruiting NCT04132986 - Study of Absorbable Biosynthetic Meshes in Contaminated Ventral Hernia Repair